Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Exxon Mobil Corporation — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Exxon Mobil Corporation trades at $177.94 (market cap $715.80B). The key difference: Exxon Mobil Corporation is far larger — about 146.7× Travere Therapeutics Inc. Common Stock's market cap, and Exxon Mobil Corporation pays a 2.37% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Exxon Mobil Corporation for 100 Days on average.
| TVTX | XOM | |
|---|---|---|
Market Cap | $4.88B | $715.80B |
Volume | 1,668,577 | 11,362,664 |
Sector | Health | Energy |
52-Week High | $67.52 | $177.06 |
52-Week Low | $26.79 | $110.64 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $5.01B | $747.58B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
ExxonMobil (XOM) trades at $172.15, up 1.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $323.91B in 2025 (SEC filing, 2025), though net income margin remains solid at 9.07%. Recent news highlights potential expansion into Venezuela's oil fields (Reuters, 2026-09-16) and operational updates in Guyana and Angola, supporting long-term growth targets.
The stock offers value with a P/E of 22.4 and strong cash flow, but faces headwinds from volatile oil prices and execution risks in new ventures. Analyst consensus is mixed with a $166.67 price target (MarketBeat, 2026-09-17), suggesting cautious optimism amid geopolitical and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
